Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2008

View Archived Issues

Pim-2 kinase inhibitors identified as potential drugs for the treatment of inflammation

CB2 ligands developed at Abbott undergoing optimization

Urotensin-II receptor antagonist optimization leads to JNJ-39327041

Characterization of Pfizer's novel CP-690550 in de novo kidney transplant patients

Novel antiviral agents claimed by Novartis

Oncothyreon presents update on clinical development activities

Chelsea Therapeutics initiates patient dosing in Study 301 phase III trial of droxidopa in NOH

Neurocrine presents elagolix PETAL study results in endometriosis

FDA approves Sandoz's Omnitrope Pen 10 with liquid cartridge for growth hormone deficiency

PHA-848125, a novel CDK inhibitor orally active in preclinical model of ovarian carcinoma

Ikaria acquires North American rights to Lucassin for HRS from Orphan Therapeutics

Refinement of H3 receptor antagonists for wakefulness continues at Arena Pharmaceuticals

Wyeth advances synthesis of dual selective serotonin reuptake inhibitors/5-HT1A antagonists

Diffusion initiates phase I/II trans-sodium crocetinate trial in patients with PAD

Recent patents cover novel anticancer agents

OSI initiates clinical development program for antidiabetes candidate, PSN-821

Plexxikon commences phase I trial for novel kinase inhibitor, PLX-5568

New immunmodulatory agents disclosed by Otsuka Chemical

Sangamo BioSciences initiates phase II trial for SB-509 in ALS

Agile achieves phase II study endpoints with low-dose contraceptive patch

Phase II study shows Arcalyst reduces gout flares by 81%

OncoGenex grants Eagle Pharmaceuticals exclusive worldwide rights to Tocosol paclitaxel

Anavex successfully completes preclinical studies of ANAVEX 2-73 in Alzheimer's disease

Dako acquires InstrumeC

ZymoGenetics and Merck Serono restructure 2001 partnership agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 23, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 23, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...